Contents:
Document Title
Prescribing and administration of CSCI (continuous subcutaneous infusion) furosemide for heart failure patients who are at end of life
Document Date
November 2022
Document Purpose and Intended Audience
The aim of these guidelines is to ensure staff are informed and able to manage patients who require treatment with continuous subcutaneous infusions of furosemide at end of life.
These guidelines are suitable for use in both primary community
care and in the in-patient setting.
Authors
Christina Radcliffe, Consultant Palliative Medicine St Mary’s Hospice, Birmingham.
Karen Green, Palliative Urgent Response Team Leader Sandwell and West Birmingham NHS Trust.
Consultation Process
C. Radcliffe and K. Green reviewed and updated the guidelines.
Subsequently reviewed and endorsed by SPAGG
Reviewed by Dr A Reynolds 2022
Monitoring
Monitoring of guideline implementation locally
Review Date
(must be within three years)
November 2025
Approval Signatures:
SPAGG chair
Dr Jon Tomas
SPAGG secretary
Dr Alice Gray
Date Approved by SPAGG: November 2022
Date submitted to Area Prescribing Committee: N/A
Version History
Version 0.1
Date
Dc 2022
Summary of change/ process
Expansion on importance of MDT decision making
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.